|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 4 |
| 2 | Granulocyte Colony–Stimulating Factor Mobilizes CD34 + Cells and Improves Survival of Patients With Acute-on-Chronic Liver Failure显示文摘 | Vishal Garg Hitendra Garg Arshi Khan Nirupama Trehanpati Ashish Kumar Barjesh Chander Sharma Puja Sakhuja Shiv Kumar Sarin | 2012 | Gastroenterology2012，，3： | 3 |
| 3 | Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism显示文摘BACKGROUND Gastrointestinal cancer(GICA)is associated with a higher incidence of venous thromboembolism(VTE)compared to other solid tumors,moreover,recurrent VTE and major bleeding(MB)complications during anticoagulation treatment have an associated increase rate.GICA-VTE remains a challenging clinical scenario with MB concerns for utilization of direct oral anticoagulants(DOAC),especially with active cancer therapies.AIM To evaluate patient risk factors,effectiveness(VTE)and safety(MB)of DOACs and low molecular weight heparin(LMWH)in patients with active GICA-VTE.METHODS A retrospective chart review of patients receiving DOACs and LMWH with GICA and symptomatic or incidental VTE treated at comprehensive cancer center from November 2013 to February 2017 was performed.Inclusion criteria included active GI cancer diagnosed at any stage or treatment+/-6 mo of VTE diagnosis,whom were prescribed 6 mo or more of DOACs or LMWH.The Chi-squared test was used for overall and the Fisher exact test for pairwise comparisons of the proportions of patients experiencing recurrent VTE and MB events.Odds ratios were used to compare the relative odds of the occurrence of the outcome given exposure to the risk factor.RESULTS A total of 144 patients were prescribed anticoagulation,in which 106 fulfilled inclusion criteria apixaban(27.3%),rivaroxaban(34.9%)and enoxaparin(37.7%),and 38 were excluded.Patients median age was 66.5 years at GICA diagnosis and 67 years at CAVTE event,with 62%males,80%Caucasian,70%stage IV,pancreatic cancer(40.5%),30%Khorana Score(≥3 points),and 43.5%on active chemotherapy.Sixty-four percent of patients completed anticoagulation therapy(range 1 to 43 mo).Recurrent VTE at 6 mo was noted in 7.5%(n=3),6.8%(n=2)and 2.7%(n=1)of patients on enoxaparin,apixaban and rivaroxaban,respectively(all P=NS).MB at 6 mo were 5%(n=2)for enoxaparin,6.8%(n=2)for apixaban and 21.6%(n=8)for rivaroxaban(overall P=0.048;vs LMWH P=0.0423;all other P=NS).Significant predictors of a primary or secondary outcome for all anticoagulation therapies included:Active systemic treatment(OR=5.1,95%CI:1.3-19.3),high Khorana Score[≥3 points](OR=5.5,95%CI:1.7-17.1),active smoker(OR=6.7,95%CI:2.1-21.0),pancreatic cancer(OR=6.8,95%CI:1.9-23.2),and stage IV disease(OR=9.9,95%CI:1.2-79.1).CONCLUSION Rivaroxaban compared to apixaban and enoxaparin had a significantly higher risk of MB on GICA-VTE patients with equivocal efficacy. | Alejandro Recio-Boiles Sumana Veeravelli Jessica Vondrak Hani M Babiker Aaron J Scott Rachna T Shroff Hitendra Patel Emad Elquza Ali McBride | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 3 |
| 4 | Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure显示文摘 | Hitendra Garg Ashish Kumar Vishal Garg Praveen Sharma Barjesh Chander Sharma Shiv Kumar Sarin | 2011 | Digestive and Liver Disease2011，，2： | 3 |
| 5 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 2 |
| 6 | Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute‐on‐chronic liver failure显示文摘 | Hitendra Garg Ashish Kumar Vishal Garg Manoj Kumar Ramesh Kumar Barjesh Chander Sharma Shiv Kumar Sarin | 2013 | J Gastroenterol Hepatol2013，，8： | 2 |
| 7 | Human tissue factor pathway inhibitor-2 does not bind or inhibit activated matrix metalloproteinase-1显示文摘 | Xin Du Hitendra S. Chand Walter Kisiel | 2003 | BBA - General Subjects2003，，3： | 2 |
| 8 | Biosorption of aqueous chromium(VI) by Tamarindus indica seeds显示文摘 | G.S. Agarwal Hitendra Kumar Bhuptawat Sanjeev Chaudhari | 2005 | Bioresource Technology2005，，7： | 1 |
| 9 | Innovative pHysico-chemical treatment of wastewater incorporating Moringa oleifera seed coagulant显示文摘 | Hitendra B Folkard G K Sanjeev C | 2007 | Journal of Hazardous Materials2007，142，： | 1 |
| 10 | Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma显示文摘Tumor biopsies may help to reliably distinguish hepatocellular carcinoma(HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies. Clarifying tumor biology may also lead to identify biomarkers with prognostic role and/or enabling to predict response or resistance to therapies. Recently, clinical trials have more efficiently included biomarker endpoints and increasingly collected tumor tissue from enrolled patients. Due to their frail status and sometimes fast-progressing disease, the performance status of patients with HCC progressing on first-line therapy can deteriorate quickly, preventing their enrollment in clinical trials. However, the challenge of identifying the proper patient at the proper time can be overcome by periodic inter-department meetings involving the key specialists taking care of HCC patients, and solid networks between research centers and referring institutions. An early planned biopsy would also facilitate timely inclusion of patients in biology-driven clinical trials. Ultimately, institution of multidisciplinary teams can optimize treatment choice, biopsy timing, and quick enrollment of patients in clinical trials, before their performance status deteriorates. | Lorenza Rimassa Maria Reig Giovanni Abbadessa Markus Peck-Radosavljevic William Harris Vittorina Zagonel Davide Pastorelli Elena Rota Caremoli Camillo Porta Nevena Damjanov Hitendra Patel Bruno Daniele Maria Lamar Brian Schwartz Terri Goldberg Armando Santoro Jordi Bruix | 2017 | World Journal of Gastroenterology2017，23，13： | 1 |
| 11 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 1 |
| 12 | Understanding learning behaviour of Malaysian adult learners: a cross-cultural sensitive framework显示文摘 | Po Li Tan Hitendra Pillay | 2008 | Educational Research for Policy and Practice2008，，2： | 1 |
| 13 | Synthesis of 4-aryl aubstituted 3,4-Dihydropyrimidinones using silica-cldoride under solvent free conditions显示文摘 | HITENDRA N K MANISHA S KAUSHIK M P | 2007 | Molecules2007，12，： | 1 |
| 14 | Controlled attenuation parameter for non‐invasive assessment of hepatic steatosis: Does etiology affect performance?显示文摘 | Manoj Kumar Archana Rastogi Tarandeep Singh Chhagan Behari Ekta Gupta Hitendra Garg Ramesh Kumar Vikram Bhatia Shiv K Sarin | 2013 | J Gastroenterol Hepatol2013，，7： | 1 |
| 15 | Altered Frequencies of Dendritic Cells and IFN ‐γ‐secreting T Cells with Granulocyte Colony‐Stimulating Factor (G‐ CSF ) Therapy in Acute‐on‐Chronic Liver Failure显示文摘 | Arshi Khanam Nirupama Trehanpati Vishal Garg Chandan Kumar Hitendra Garg Barjesh C. Sharma Shiv K. Sarin | 2014 | Liver Int2014，，4： | 1 |
| 16 | Liver Stiffness Measurements in Patients with Different Stages of Nonalcoholic Fatty Liver Disease: Diagnostic Performance and Clinicopathological Correlation显示文摘 | Ramesh Kumar Archana Rastogi Manoj Kumar Sharma Vikram Bhatia Pankaj Tyagi Praveen Sharma Hitendra Garg K. N. Chandan Kumar Chhagan Bihari Shiv Kumar Sarin | 2013 | Digestive Diseases and Sciences2013，，1： | 1 |
| 17 | Nanoemulsion containing a synergistic combination of curcumin and quercetin for nose-to-brain delivery:In vitro and in vivo studies显示文摘Objective:To characterize a nanoemulsion containing a synergistic combination of curcumin(CUR)and quercetin(QUE)for brain targeting through the nose.Methods:The synergistic activity of the combination of two phytoconstituents,curcumin and quercetin(CUR-QUE)was determined at a 2:1 ratio.Nanoemulsions containing the synergistic combination were prepared using high-pressure homogenization technique.Nanoemulsion formulation was characterized for globule size,drug content,thermodynamic stability,zeta potential measurement,and drug release.Histological studies were performed using isolated nasal mucosa of sheep.Moreover,in vivo studies using allograft model were performed.Results:CUR-QUE in a 2:1 ratio combination showed the lowest combination index values 0.99(combination index<1)for treatment of human glioblastoma U373-MG cell.The combination inhibited the growth of human glioblastoma U373 MG cells.The significant drug targeting efficiency percentage(178.25±2.86 for CUR and 170.54±6.11 for QUE)and nose to brain drug direct transport percentage(44.05±0.93 for CUR and 38.25±0.83 for QUE)of optimized nanoemulsion(F9)indicated effective central nervous system targeting via the intranasal route.In vivo anticancer study using allograft model of nude mice demonstrated potential anticancer activity of the synergistic combination of CUR-QUE as compared to doxorubicin.Conclusions:This study demonstrates that synergistic combination of CUR-QUE was optimal for treatment of human glioblastoma.Moreover,significant site-specific delivery to the brain was achieved by administering nanoemulsion through the nose.The study also reveals that intranasal delivery of nanoemulsion containing synergistic combination of CUR and QUE could be a promising strategy for brain tumor treatment. | Hitendra S Mahajan Nayana D Patil | 2021 | Asian Pacific Journal of Tropical Biomedicine2021，11，11： | 1 |
| 18 | Early ECG Abnormalities Associated with Transcatheter Closure of Atrial Septal Defects Using the Amplatzer? Septal Occluder显示文摘 | Sharon L. Hill Charles I. Berul Hitendra T. Patel Jonathan Rhodes Stacey E. Supran Qi-Ling Cao Ziyad M. Hijazi | 2000 | Journal of Interventional Cardiac Electrophysiology2000，，3： | 1 |
| 19 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 1 |
| 20 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)显示文摘 | Shiv Kumar Sarin Ashish Kumar John A. Almeida Yogesh Kumar Chawla Sheung Tat Fan Hitendra Garg H. Janaka Silva Saeed Sadiq Hamid Rajiv Jalan Piyawat Komolmit George K. Lau Qing Liu Kaushal Madan Rosmawati Mohamed Qin Ning Salimur Rahman Archana Rastogi St | 2009 | Hepatology International2009，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员